| Literature DB >> 34831747 |
Cristina M Beltran-Aroca1, Rafael Ruiz-Montero2, Antonio Llergo-Muñoz3, Leticia Rubio4, Eloy Girela-López1.
Abstract
BACKGROUND: The COVID-19 pandemic outbreak has severely affected healthcare organizations worldwide, and the provision of palliative care (PC) to cancer patients has been no exception. The aim of this paper was to analyse the levels of health care provided by the Clinical Management Unit for PC in Córdoba (Spain) for cancer patients.Entities:
Keywords: COVID-19; cancer; ethical issues; legal medicine; palliative care; pandemic
Mesh:
Year: 2021 PMID: 34831747 PMCID: PMC8618945 DOI: 10.3390/ijerph182211992
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 4.614
Figure 1Flow chart of the sample.
Parameters analysed.
|
| Gender | Male/Female |
| Age | Years | |
| Main caregiver | FDR 1; SDR 2; other relatives; professionals | |
|
| Cancer | Type of oncological process |
| Metastasis | Presence or absence | |
| Complexity [ | Non-complex situation; complex; highly complex discharge | |
| Reason for leaving program | Discharge; death | |
| Karnofsky Performance Status scale (KPS) | Ability to perform routine tasks (0–100) | |
| Eastern Cooperative | Cancer patient’s quality of life (0–5) | |
|
| Referred from | Primary care; outpatient care; inpatient care; emergency care and other |
| CMU 3 of origin | Type of CMU | |
| Derivation priority | Normal; Urgent; Preferential | |
| Place of death | Home; general hospital; PC hospital; emergency ward; others | |
| Total delay | Time from patient referral to PC to inclusion in program (days) | |
| Length of stay in program (patient’s survival) | Time from patient being attended to patient leaving program (days) | |
|
| Advance vital directives | Document registered by patient (yes/no) |
| Knowledge of patient and family | Degree of patient’s knowledge of real situation (not informed; partial; full knowledge; not applicable) | |
| Assessment of patient and family | Degree of assessment and understanding of patient’s situation (not informed; partial; full knowledge; not applicable) |
1 FDR: first degree relative. 2 SDR: second degree relative. 3 CMU: clinical management unit.
Scales analysed.
| Scale | Points | Description |
|---|---|---|
| 0 | Dead | |
| 10 | Moribund | |
| 20 | Completely bedridden, very sick, hospital admission necessary; active support treatment necessary | |
| 30 | Severely disabled; hospital admission indicated, and active supportive treatment given | |
| 40 | Disabled, requires special care and assistance. Bedridden for over half the day. | |
| 50 | Requires considerable assistance and frequent medical. Bedridden for less than half the day. | |
| 60 | Requires occasional assistance but is able to care for most personal needs | |
| 70 | Cares for self; unable to carry on normal activity or do active work | |
| 80 | Able to perform normal activity with effort; some signs and symptoms of disease | |
| 90 | Able to carry on normal activity; minor signs and symptoms of disease | |
| 100 | Normal, no complaints, no evidence of disease | |
| 0 | Completely asymptomatic, fully able to do work and everyday activities | |
| 1 | Shows symptoms that do not prevent them from doing their work or everyday activities | |
| 2 | Unable to carry out any work activities, with symptoms which force them to stay in bed for several hours a day | |
| 3 | Confined to bed or chair for more than half the day due to the existence of symptoms | |
| 4 | Totally confined to bed or chair all day and needing help with all everyday activities | |
| 5 | Dying or will die within hours |
1 KPS: Karnofsky Performance Status scale. 2 ECOG: Eastern Cooperative Oncology Group scale.
Figure 2Distribution of diseases treated by PC before and during the pandemic * (p = 0.008).
Sociodemographic data of the patients before and during the pandemic.
| Pre-Pandemic | Pandemic | ||
|---|---|---|---|
| Gender | 0.027 | ||
| Males | 743 (61%) | 418 (55.8%) | |
| Females | 476 (39%) | 330 (44.2%) | |
| Age (years) | 0.574 | ||
| Median [IQR] 1 | 75.69 [64.98–83.73] | 75.61 [65.25–84.67] | |
| Caregivers | |||
| FDR 2 |
|
| 0.008 |
| SDR 3 | 57 (4.7%) | 43 (5.7%) | |
| OR 4 |
|
| |
| Professionals |
|
|
1 IQR: interquartile range, 2 FDR: first degree relative, 3 SDR: second degree relative, 4 OR: other relative. Bold: the bold marks statistically significant differences between both groups.
Data on the patients’ clinical situation.
| Pre-Pandemic | Pandemic | ||
|---|---|---|---|
| Type of cancer | 0.242 | ||
| Lung | 270 (22.2%) | 136 (18.2%) | |
| Intracranial | 37 (3%) | 21 (2.8%) | |
| Haematological | 63 (5.2%) | 39 (5.2%) | |
| Prostate | 41 (3.4%) | 27 (3.6%) | |
| Urinary Tract | 83 (6.8%) | 58 (7.8%) | |
| Colorectal | 207 (17%) | 138 (18.5%) | |
| Breast | 78 (6.4%) | 52 (6.9%) | |
| Head-neck | 63 (5.2%) | 23 (3.1%) | |
| Genitals | 72 (5.9%) | 51 (6.8%) | |
| Oesophagus-stomach | 87 (7.1%) | 48 (6.4%) | |
| Liver | 49 (4%) | 33 (4.4%) | |
| Pancreas-bile ducts | 122 (10%) | 78 (10.4%) | |
| Bone | 1 (0.1%) | 4 (0.6%) | |
| Others | 45 (3.7%) | 40 (5.3%) | |
| Presence of metastasis | 0.156 | ||
| Yes | 469 (38.5%) | 313 (41.8%) | |
| Complexity | 0.020 | ||
| Not complex | 800 (65.6%) | 459 (61.3%) | |
| 1 complex element | 151 (12.4%) | 70 (9.3%) | |
| Several complex elements | 33 (2.7%) | 19 (2.6%) | |
| Highly complex |
|
| |
| KPS 1 (points) | 0.141 | ||
| 10 | 22 (1.8%) | 21 (2.8%) | |
| 20 | 61 (5%) | 26 (3.5%) | |
| 30 | 168 (13.8%) | 70 (9.3%) | |
| 40 | 261 (21.4%) | 153 (20.4%) | |
| 50 | 464 (38.1%) | 318 (42.5%) | |
| 60 | 191 (15.7%) | 121 (16.2%) | |
| 70 | 27 (2.2%) | 17 (2.3%) | |
| 80 | 11 (0.9%) | 17 (2.3%) | |
| 90 | 9 (0.7%) | 1 (0.2%) | |
| 100 | 5 (0.4%) | 4 (0.5%) | |
| ECOG 2 (points) | <0.001 | ||
| 0 | 12 (1%) | 0 (0%) | |
| 1 | 40 (3.3%) | 13 (1.7%) | |
| 2 |
|
| |
| 3 |
|
| |
| 4 |
|
| |
| 5 | 12 (1%) | 7 (0.9%) | |
| Reason for ending program | <0.001 | ||
| Discharge | 7 (0.6%) | 22 (2.9%) | |
| Death |
|
|
1 KPS: Karnofsky Performance Status scale: a lower score indicates a worse patient survival and quality of life. 2 ECOG: Eastern Cooperative Oncology Group scale: a higher score indicates a poorer performance status. Bold: the bold marks statistically significant differences between both groups.
Data on the healthcare provided.
| Pre-Pandemic | Pandemic | ||
|---|---|---|---|
| Referral from | <0.001 | ||
| Primary care |
|
| |
| Outpatient care | 539 (44.2%) | 312 (41.7%) | |
| Inpatient care |
|
| |
| Emergency and other | 5 (0.4%) | 8 (1.1%) | |
| CMU 1 | 0.326 | ||
| Cardiology | 5 (0.4%) | 1 (0.2%) | |
| Plastic surgery | 4 (0.2%) | 3 (0.6%) | |
| General surgery | 44 (3.6%) | 24 (3.2%) | |
| Thoracic surgery | 0 (0%) | 1 (0.2%) | |
| Digestive | 126 (10.3%) | 74 (9.9%) | |
| Pain unit | 0 (0%) | 1 (0.2%) | |
| Gynaecology | 6 (0.5%) | 13 (1.7%) | |
| Home hospital treatment | 0 (0%) | 1 (0.2%) | |
| Haematology | 51 (4.2%) | 31 (4.1%) | |
| Infectious diseases | 2 (0.2%) | 1 (0.2%) | |
| Maxillofacial surgery | 6 (0.5%) | 2 (0.3%) | |
| Internal medicine | 121 (9.9%) | 79 (10.7%) | |
| Nephrology | 2 (0.2%) | 1 (0.2%) | |
| Neurosurgery | 13 (1.1%) | 8 (1.1%) | |
| Pneumology | 67 (5.5%) | 26 (3.5%) | |
| Neurology | 6 (0.5%) | 4 (0.6%) | |
| Oncology | 701 (57.5%) | 427 (57.2%) | |
| ENT 2 | 4 (0.3%) | 5 (0.9%) | |
| Oncology RT | 23 (1.9%) | 17 (2.3%) | |
| Interventional X-ray 3 | 0 (0%) | 1 (0.2%) | |
| Traumatology | 1 (0.1%) | 0 (0%) | |
| UCI | 2 (0.2%) | 0 (0%) | |
| Emergencies | 2 (0.2%) | 0 (0%) | |
| Urology | 32 (2.6%) | 23 (3.2%) | |
| Priority | 0.153 | ||
| Normal (no priority) | 1108 (90.9%) | 663 (88.7%) | |
| Urgent (priority 1) | 16 (1.3%) | 8 (1.1%) | |
| Preferential (priority 2) | 95 (7.8%) | 76 (10.2%) | |
| Delay (days) | 0.016 | ||
| Average [IQR] 4 | 1 [0–0] | 1 [0–0] | |
| Place of death | <0.001 | ||
| Home | 609 (50.3%) | 422 (58.1%) | |
| General hospital | 165 (13.6%) | 110 (15.2%) | |
| Palliative hospital |
|
| |
| Emergencies | 17 (1.4%) | 8 (1.1%) | |
| Others | 17 (1.4%) | 2 (0.3%) |
1 CMU: clinical management unit. 2 ENT: ear, nose & throat/otolaryngology. 3 Interventional X-ray: interventional radiology. 4 IQR: interquartile range. Bold: the bold marks statistically significant differences between both groups.
ECOG score analysis according to referral location.
| Pre-Pandemic | Pandemic | |||
|---|---|---|---|---|
| Referral from | ECOG 1 (points) | |||
| Primary care | 0 | 2 (1%) | 0 (0%) | <0.001 |
| 1 | 7 (3.5%) | 0 (0%) | ||
| 2 |
|
| ||
| 3 |
|
| ||
| 4 | 45 (22.4%) | 15 (18.8%) | ||
| 5 | 0 (0%) |
| ||
| Outpatient care | 0 | 6 (1.1%) | 0 (0%) | <0.001 |
| 1 | 22 (4.1%) | 6 (1.9%) | ||
| 2 |
|
| ||
| 3 |
|
| ||
| 4 | 68 (12.6%) | 45 (14.4%) | ||
| 5 | 2 (0.4%) | 3 (1%) | ||
| Inpatient care | 0 | 4 (0.8%) | 0 (0%) | <0.001 |
| 1 | 10 (2.1%) | 7 (2%) | ||
| 2 |
|
| ||
| 3 |
|
| ||
| 4 |
|
| ||
| 5 |
|
| ||
| Emergency and other | 0 | 0 (0%) | 0 (0%) | 0.325 |
| 1 | 1 (20%) | 0 (0%) | ||
| 2 | 4 (80%) | 7 (87.5%) | ||
| 3 | 0 (0%) | 0 (0%) | ||
| 4 | 0 (0%) | 0 (0%) | ||
| 5 | 0 (0%) | 1 (12.5%) |
1 ECOG: Eastern Cooperative Oncology Group scale: a higher score indicates a poorer performance status. Bold: the bold marks statistically significant differences between both groups.
Risk analysis for permanence in the palliative care program.
| HR 1 | 95% CI 2 | ||
|---|---|---|---|
| Pandemic | |||
| Pre-pandemic (reference) | |||
| Pandemic | 0.99 | 0.82–1.20 | 0.931 |
| Age (decades/years) | 0.89 | 0.84–0.95 | <0.001 |
| Gender | |||
| Male (reference) | |||
| Female | 0.79 | 0.67–0.93 | 0.005 |
| Presence of metastasis | |||
| No (reference) | |||
| Yes | 1.48 | 1.25–1.75 | <0.001 |
| KPS 3 | 0.84 | 0.78–0.91 | <0.001 |
| ECOG 4 | 1.16 | 1.02–1.31 | 0.024 |
| Referral from | |||
| Primary care (reference) | |||
| Outpatient care | 0.74 | 0.59–0.94 | 0.012 |
| Inpatient care | 1.00 | 0.78–1.27 | 0.968 |
| Emergencies and other | 0.99 | 0.23–4.18 | 0.988 |
| Priority | |||
| Normal (reference) | |||
| Urgent | 8.11 | 2.96–22.18 | <0.001 |
| Preferential | 1.38 | 1.06–1.81 | 0.017 |
1 HR: Hazard Ratio from Cox regression analysis. 2 CI: Confidence Interval. 3 KPS: Karnofsky Performance Status scale. 4 ECOG: Eastern Cooperative Oncology Group scale.
Data on patients’ degree of knowledge and preferences.
| Pre-Pandemic | Pandemic | ||
|---|---|---|---|
| ADLW 1 registered | 1.000 | ||
| Yes | 13 (1.1%) | 7 (1%) | |
| Patient’s knowledge | 0.192 | ||
| Not informed | 161 (13.2%) | 93 (12.4%) | |
| Partial knowledge | 375 (30.8%) | 276 (36.9%) | |
| Full knowledge | 683 (56%) | 379 (50.7%) | |
| Patient’s assessment | <0.001 | ||
| Not informed | 166 (13.6%) | 90 (12%) | |
| Partial knowledge | 66 (5.4%) | 31 (4.2%) | |
| Full knowledge |
|
| |
| Not known/Not applicable | 329 (27%) | 116 (15.5%) | |
| Family’s knowledge | 0.351 | ||
| Not informed | 1 (0.1%) | 4 (0.6%) | |
| Partial knowledge | 30 (2.5%) | 29 (3.9%) | |
| Full knowledge | 1176 (96.5%) | 706 (94.4%) | |
| Not known/Not applicable | 11 (0.9%) | 8 (1.1%) | |
| Family’s assessment | 0.683 | ||
| Not informed | 76 (6.2%) | 54 (7.2%) | |
| Partial knowledge | 29 (2.4%) | 10 (1.4%) | |
| Full knowledge | 1100 (90.2%) | 673 (90%) | |
| Not known/Not applicable | 15 (1.2%) | 10 (1.4%) |
1 ADLW: advance directive living will. Bold: the bold marks statistically significant differences between both groups.